Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Angiotensin Ii. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.84 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.84 |
| ▸ | REN | P00797 | 3/20 | 0.66 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.62 |
| ▸ | ANPEP | P15144 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL13232382 | 1.00 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL2566771 | 1.00 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL21267957 | 0.99 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL3465991 | 0.99 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL14990505 | 0.99 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL1585377 | 0.99 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL8898391 | 0.99 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL2183118 | 0.99 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL21408200 | 0.98 | AGTR2 (0.82) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL513519 | 0.98 | AGTR2 (0.82) | AGTR2AGTR1RENLNPEPANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 85971 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146232-A1 | METHODS FOR PROMOTING HOMING AND ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2026-05-28 | — | — | US | claimed |
| CN-122074448-A | Progressive pathological animal model for drug evaluation and construction method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081202-A | Application of small molecule tripeptide Ser-Ser-Cys in inhibiting vascular smooth muscle cell phenotype switching | — | 2026-05-26 | — | — | CN | claimed |
| CN-122070939-A | Use of agent for over-expressing Parp7 in preparation of medicine for treating hypertensive nephropathy and protecting sepsis acute kidney injury | 嘉兴市第二医院 | 2026-05-22 | — | — | CN | claimed |
| CN-122017228-A | Colloidal gold method for rapidly detecting ACE inhibition activity and test paper preparation | 东北农业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-0062277-A1 | A method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays | Baker Instruments Corporation (US) | 1982-10-13 | — | — | EP | claimed |
| US-4283407-A | ANTIHYPERTENSIVE AGENTS | SCIENCE UNION ET CIE (FR) | 1981-08-11 | — | — | US | claimed |
| EP-0010347-A1 | Novel substituted omega-aroyl(propionyl or butyryl)-L-prolines, pharmaceutical compositions containing them and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-04-30 | — | — | EP | claimed |
| US-4128653-A | Reduction of blood pressure with carboxyalkylacyl-pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | claimed |
| US-4108726-A | Sarcoidosis test | RESEARCH CORPORATION (US) | 1978-08-22 | — | — | US | claimed |
| US-4086338-A | HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1978-04-25 | — | — | US | claimed |
| US-4052511-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-04 | — | — | US | claimed |
| US-4046889-A | HYPOTENSIVE AGENTS, ENZYME INHIBITORS, ANGIOTENSIN CONVERSION | E. R. SQUIBB & SONS, INC. (US) | 1977-09-06 | — | — | US | claimed |
| US-3947575-A | Peptides as argiotensin converting enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1976-03-30 | — | — | US | claimed |
| US-3932624-A | Method for prolonging the inhibitory effect of saralasin on angiotensin II | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-01-13 | — | — | US | claimed |